Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boaz Nachmias

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Acta Haematologica|October 22, 2018
A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaBoaz Nachmias, Adir Shaulov, Moshe E Gatt, et al.
Leukemia & Lymphoma|October 3, 2018
Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicityVipul Sheth, Boaz Nachmias, Sigal Grisariu, et al.
Journal of Clinical Medicine|April 12, 2022
Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple MyelomaEyal Lebel, Boaz Nachmias, Marjorie Pick, et al.
International Journal of Molecular Sciences|September 23, 2022
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic LeukemiaShlomzion Aumann, Adir Shaulov, Arnon Haran, et al.
Cancer Medicine|November 24, 2021
Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective studyYael Morgenstern, Shlomzion Aumann, Neta Goldschmidt, et al.
Transfusion|March 3, 2023
Successful treatment with plasma exchange in life-threatening hyperhemolytic syndrome unrelated to sickle cell diseaseAdir Shaulov, Deborah Rund, Dvora Filon, et al.
Cancer Research|June 25, 2009
The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicityIhab Abd-Elrahman, Klilah Hershko, Tzahi Neuman, et al.
Oncology Research and Treatment|December 9, 2020
Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System LymphomaStav Gazal, Eyal Lebel, Yosef Kalish, et al.
Clinical Nuclear Medicine|May 21, 2020
Posttreatment FDG-Avid Splenic Lesions in DLBCL and HD: Clinical and Radiographic Characteristics for Risk AssessmentBoaz Nachmias, Jeremy Godefroy, Eyal Rozenbach, et al.
Frontiers in Immunology|February 11, 2025
Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-ThymoglobulinItai Falicovich, Boaz Nachmias, Shlomo Elias, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Acta Haematologica|October 22, 2018
A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaBoaz Nachmias, Adir Shaulov, Moshe E Gatt, et al.
Leukemia & Lymphoma|October 3, 2018
Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicityVipul Sheth, Boaz Nachmias, Sigal Grisariu, et al.
Journal of Clinical Medicine|April 12, 2022
Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple MyelomaEyal Lebel, Boaz Nachmias, Marjorie Pick, et al.
International Journal of Molecular Sciences|September 23, 2022
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic LeukemiaShlomzion Aumann, Adir Shaulov, Arnon Haran, et al.
Cancer Medicine|November 24, 2021
Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective studyYael Morgenstern, Shlomzion Aumann, Neta Goldschmidt, et al.
Transfusion|March 3, 2023
Successful treatment with plasma exchange in life-threatening hyperhemolytic syndrome unrelated to sickle cell diseaseAdir Shaulov, Deborah Rund, Dvora Filon, et al.
Cancer Research|June 25, 2009
The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicityIhab Abd-Elrahman, Klilah Hershko, Tzahi Neuman, et al.
Oncology Research and Treatment|December 9, 2020
Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System LymphomaStav Gazal, Eyal Lebel, Yosef Kalish, et al.
Clinical Nuclear Medicine|May 21, 2020
Posttreatment FDG-Avid Splenic Lesions in DLBCL and HD: Clinical and Radiographic Characteristics for Risk AssessmentBoaz Nachmias, Jeremy Godefroy, Eyal Rozenbach, et al.
Frontiers in Immunology|February 11, 2025
Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-ThymoglobulinItai Falicovich, Boaz Nachmias, Shlomo Elias, et al.
Pageof 6